EMVision Medical Devices (EMV) investor relations material

Technology and innovation

• Developed portable brain scanners using radio frequency signals, representing a world-first modality for stroke and traumatic brain injury care.

• Devices are lightweight, non-ionizing, and designed for both in-hospital and pre-hospital use, enabling broader and more equitable access.

• AI models interpret proprietary signal data to differentiate between types of brain injuries at the point of care.

• Clinical design involved direct collaboration with end users to ensure practical utility.

• Patent portfolio spans hardware and software, with multiple grants in the U.S., Europe, and Asia.

Clinical and market validation

• Completed a successful multi-site study in Australia, achieving high accuracy in hemorrhage and ischemia detection.

• Ongoing pivotal clinical trial in the U.S. and Australia will support FDA De Novo submission, with similar data planned for TGA and CE marking.

• Collaborations include Keysight (largest shareholder, co-developer of components) and the Australian Stroke Alliance (major grant support).

• Additional support from NVIDIA’s Inception program for AI model training and high-performance computing.

• Multiple grants, including AUD 4 million from the Industry Growth Program and CRC-P for regional studies.

Market opportunity and commercialization

• Addressable markets include 10,000 U.S. hospitals, 60,000 ambulances, and significant international potential.

• Revenue model based on capital equipment, consumables, and service, targeting high industry margins.

• Expansion into traumatic brain injury expected to increase consumable revenue.

• Workflow improvements in hospitals and ambulances can generate meaningful time savings and better patient outcomes.

• Pre-hospital and aeromedical markets are high priorities due to the potential for rapid diagnosis and treatment.